Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. more
Time Frame | MCRB | Sector | S&P500 |
---|---|---|---|
1-Week Return | 4.2% | -2.12% | -3% |
1-Month Return | 12.48% | -3.42% | -0.73% |
3-Month Return | -18.98% | -11.13% | 2.87% |
6-Month Return | 21.82% | -5.74% | 7.17% |
1-Year Return | -14.44% | 3.97% | 25.31% |
3-Year Return | -89.27% | 1.05% | 28.38% |
5-Year Return | -77.67% | 34.37% | 81.89% |
10-Year Return | -98.22% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 34.51M | 33.22M | 144.93M | 7.13M | 126.33M | [{"date":"2019-12-31","value":23.81,"profit":true},{"date":"2020-12-31","value":22.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.92,"profit":true},{"date":"2023-12-31","value":87.16,"profit":true}] |
Cost of Revenue | 80.14M | 90.57M | 1.73M | 1.00M | 704.00K | [{"date":"2019-12-31","value":88.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":1.91,"profit":true},{"date":"2022-12-31","value":1.11,"profit":true},{"date":"2023-12-31","value":0.78,"profit":true}] |
Gross Profit | (45.64M) | (57.35M) | 143.19M | 6.12M | 125.62M | [{"date":"2019-12-31","value":-31.87,"profit":false},{"date":"2020-12-31","value":-40.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.28,"profit":true},{"date":"2023-12-31","value":87.73,"profit":true}] |
Gross Margin | (132.26%) | (172.68%) | 98.80% | 85.91% | 99.44% | [{"date":"2019-12-31","value":-133,"profit":false},{"date":"2020-12-31","value":-173.65,"profit":false},{"date":"2021-12-31","value":99.36,"profit":true},{"date":"2022-12-31","value":86.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 104.89M | 121.34M | 209.42M | 253.62M | 233.60M | [{"date":"2019-12-31","value":41.36,"profit":true},{"date":"2020-12-31","value":47.85,"profit":true},{"date":"2021-12-31","value":82.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.11,"profit":true}] |
Operating Income | (71.88M) | (88.13M) | (64.49M) | (246.49M) | (107.98M) | [{"date":"2019-12-31","value":-7187600000,"profit":false},{"date":"2020-12-31","value":-8813000000,"profit":false},{"date":"2021-12-31","value":-6449300000,"profit":false},{"date":"2022-12-31","value":-24649000000,"profit":false},{"date":"2023-12-31","value":-10798300000,"profit":false}] |
Total Non-Operating Income/Expense | 2.13M | (2.98M) | (1.13M) | (6.63M) | (10.02M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-139.8,"profit":false},{"date":"2021-12-31","value":-52.87,"profit":false},{"date":"2022-12-31","value":-311.51,"profit":false},{"date":"2023-12-31","value":-471.05,"profit":false}] |
Pre-Tax Income | (70.28M) | (89.13M) | (65.58M) | (250.16M) | (113.72M) | [{"date":"2019-12-31","value":-7027900000,"profit":false},{"date":"2020-12-31","value":-8912700000,"profit":false},{"date":"2021-12-31","value":-6557800000,"profit":false},{"date":"2022-12-31","value":-25015700000,"profit":false},{"date":"2023-12-31","value":-11372400000,"profit":false}] |
Income Taxes | (6.04M) | (2.67M) | (4.08M) | 3.67M | 14.95M | [{"date":"2019-12-31","value":-40.38,"profit":false},{"date":"2020-12-31","value":-17.88,"profit":false},{"date":"2021-12-31","value":-27.31,"profit":false},{"date":"2022-12-31","value":24.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (64.24M) | (86.45M) | (61.50M) | (253.82M) | (128.67M) | [{"date":"2019-12-31","value":-6424400000,"profit":false},{"date":"2020-12-31","value":-8645400000,"profit":false},{"date":"2021-12-31","value":-6149600000,"profit":false},{"date":"2022-12-31","value":-25382400000,"profit":false},{"date":"2023-12-31","value":-12867010500,"profit":false}] |
Income From Continuous Operations | (70.28M) | (89.13M) | (65.58M) | (250.16M) | (141.27M) | [{"date":"2019-12-31","value":-7027900000,"profit":false},{"date":"2020-12-31","value":-8912700000,"profit":false},{"date":"2021-12-31","value":-6557800000,"profit":false},{"date":"2022-12-31","value":-25015700000,"profit":false},{"date":"2023-12-31","value":-14127200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (64.24M) | (86.45M) | (61.50M) | (253.82M) | (113.72M) | [{"date":"2019-12-31","value":-6424400000,"profit":false},{"date":"2020-12-31","value":-8645400000,"profit":false},{"date":"2021-12-31","value":-6149600000,"profit":false},{"date":"2022-12-31","value":-25382400000,"profit":false},{"date":"2023-12-31","value":-11372400000,"profit":false}] |
EPS (Diluted) | (1.31) | (1.15) | (0.72) | (2.34) | (0.90) | [{"date":"2019-12-31","value":-131,"profit":false},{"date":"2020-12-31","value":-115,"profit":false},{"date":"2021-12-31","value":-72,"profit":false},{"date":"2022-12-31","value":-234,"profit":false},{"date":"2023-12-31","value":-90,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MCRB | |
---|---|
Cash Ratio | 1.03 |
Current Ratio | 1.12 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MCRB | |
---|---|
ROA (LTM) | -9.70% |
ROE (LTM) | -1556.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MCRB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.87 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.13 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MCRB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.24 |
P/B | 6.57 |
Price/FCF | NM |
EV/R | 1.46 |
EV/Ebitda | NM |
PEG | NM |
Seres Therapeutics Inc (MCRB) share price today is $0.9155
Yes, Indians can buy shares of Seres Therapeutics Inc (MCRB) on Vested. To buy Seres Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MCRB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Seres Therapeutics Inc (MCRB) via the Vested app. You can start investing in Seres Therapeutics Inc (MCRB) with a minimum investment of $1.
You can invest in shares of Seres Therapeutics Inc (MCRB) via Vested in three simple steps:
The 52-week high price of Seres Therapeutics Inc (MCRB) is $2.05. The 52-week low price of Seres Therapeutics Inc (MCRB) is $0.54.
The price-to-earnings (P/E) ratio of Seres Therapeutics Inc (MCRB) is
The price-to-book (P/B) ratio of Seres Therapeutics Inc (MCRB) is 6.57
The dividend yield of Seres Therapeutics Inc (MCRB) is 0.00%
The market capitalization of Seres Therapeutics Inc (MCRB) is $157.23M
The stock symbol (or ticker) of Seres Therapeutics Inc is MCRB